Dialog Box

23 June 2020

EHA 2020 Congress - Aggressive lymphoma updates

Aggressive lymphoma updates
European Hematology Association (EHA) congress

Dr Michael Dickinson, Consultant Haematologist. Disease group lead for aggressive lymphoma, Peter MacCallum Cancer Centre & Royal Melbourne Hospital

Dr Michael Dickinson spoke with Donna Gairns, National Nurse Director of Lymphoma Australia about the key abstracts for aggressive lymphomas that were presented during the EHA congress in June 2020.

Dr Dickinson spoke about emerging group of therapies that are called bispecific monoclonal antibodies and how they work. This leads to the discussion around the presentation of the clinical trial that he is leading at Peter MacCallum Cancer Centre and that was presented at the meeting during the aggressive lymphomas: cellular and bispecific antibody therapies.

Dr Dickinson also provided an update on CAR T-cells in Australia as of June 2020.

CD20-TCB in relapsed or refractory non-Hodgkin lymphoma: durable complete responses and manageable safety observed at clinically relevant doses in phase I dose escalation.

Other presentations and topics discussed through the interview:

Phase I Alexander study of AUTO3 – first bicistronic chimeric antigen receptor (CAR) targeting CD19 and CD22 with pembrolizumab in patients with relapsed or refractory diffuse large B-cell lymphoma.

Phase 3, randomised, open-label study of pembrolizumab (Pembro) versus brentuximab vedotin (BV) for treatment of relapsed or refractory classical Hodgkin lymphoma (R/R): KEYNOTE-204

PET guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma: final results of the international, randomised phase III HD17 by the GHSG.


For questions or comments, please contact Donna Gairns, National Nurse Director on 1800 953 081 or email nurse@lymphoma.org.au

Category: Research
Tags: research clinical trials aggressive lymphoma car t cell t cell therapy lymphoma expert EHA conference congress,